Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

@article{Perrillo2002PredictorsOH,
  title={Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.},
  author={Robert P. Perrillo and Ching-lung Lai and Y -F Liaw and Jules L. Dienstag and Eugene R Schiff and Solko W. Schalm and Elizabeth Jenny Heathcote and Nathaniel A. Brown and Mark Atkins and Mary A Woessner and S D Gardner},
  journal={Hepatology},
  year={2002},
  volume={36 1},
  pages={186-94}
}
Elevated alanine transaminase (ALT) levels and low serum hepatitis B virus (HBV) DNA predict a higher likelihood of hepatitis B e antigen (HBeAg) loss in patients with chronic hepatitis B treated with interferon. Predictors of HBeAg loss in patients treated with lamivudine are not known. The objective of this analysis of 4 lamivudine-controlled Phase III trials was to determine patient-dependent or laboratory variables that predict HBeAg loss. Predictors of HBeAg loss in patients treated with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 106 extracted citations

KASL clinical practice guidelines: management of chronic hepatitis B

Clinical and molecular hepatology • 2016
View 4 Excerpts
Highly Influenced

A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2015

Similar Papers

Loading similar papers…